Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
Website:
http://www.acastipharma.comNext earnings report:
12 February 2025Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 20 Nov 2024 14:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
Included in screeners
What type of business is Grace Therapeutics?
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
What sector is Grace Therapeutics in?
Grace Therapeutics is in the Healthcare sector
What industry is Grace Therapeutics in?
Grace Therapeutics is in the Biotechnology industry
What country is Grace Therapeutics from?
Grace Therapeutics is headquartered in United States
What is Grace Therapeutics website?
https://www.acastipharma.com
Is Grace Therapeutics in the S&P 500?
No, Grace Therapeutics is not included in the S&P 500 index
Is Grace Therapeutics in the NASDAQ 100?
No, Grace Therapeutics is not included in the NASDAQ 100 index
Is Grace Therapeutics in the Dow Jones?
No, Grace Therapeutics is not included in the Dow Jones index
When was Grace Therapeutics the previous earnings report?
No data
When does Grace Therapeutics earnings report?
The next expected earnings date for Grace Therapeutics is 12 February 2025